Burden of Resistant Gram Negative Bacteria in Lower Respiratory Tract Infections in ICU patients

Abstract

Background: Lower respiratory infections (LRTIs) represent the world’s deadliest infectious disease, responsible for approximately 2.5 million deaths worldwide. LRTIs are the most frequent infections among patients in the ICU (intensive care unit), often involving multidrug-resistant (MDR) pathogens.

Methods: We retrospectively analyzed 2582 clinical samples (479 sputum and 2103 endotracheal aspirates) from 2150 patients with LRTI admitted to the ICU of the Emergency Clinical County Hospital of Craiova, Romania, between 2022 and 2024.

Results: Gram-negative bacteria were responsible for 77.49% (3233) of the total of 4,172 bacterial isolates. The most frequently isolated pathogens were Klebsiella spp. (1168-36.13%), Acinetobacter spp. (935-28.92%), Pseudomonas spp. (414-12.81%), and Escherichia coli (332-10.27%). During the three-year period, the resistance rate of Acinetobacter spp. significantly increased for cefepime (from 74.09% to 94.25%, p < 0.001), imipenem (from 79.15% to 94.83%, p < 0.001), meropenem (from 88.63% to 94.95%, p < 0.05), piperacillin-tazobactam (from 86.67% to 94.39%, p = 0.001), and tigecycline (from 33.17% to 45.15%, p = 0.01). From 2022 to 2024, the resistance rate of Klebsiella spp. significantly increased for cefepime (from 47.70% to 55.71%, p < 0.05), imipenem (from 33.09% to 51.39%, p < 0.001), meropenem (from 33.09% to 52%, p < 0.001), ciprofloxacin (from 49.46% to 58.15%, p < 0.05), and levofloxacin (from 40% to 59.76%, p < 0.001). A significant decrease in resistance was found against tigecycline (from 34.91% to 13.88%, p < 0.001) and colistin (from 3.46% to 0.67%, p = 0.01). The rate of carbapenem-resistant Pseudomonas spp. strains significantly increased between 2022 and 2024 (from 41.72% to 56.93%, p = 0.01).

Conclusions: The data indicate an alarming increase in resistance to several first-line and last-resort antibiotics among Klebsiella spp. and Acinetobacter spp. strains, with progressive limitation of effective therapeutic options for ICU-LRTIs.

Key messages: • The emergence of resistant Gram-negative strains is an alarm signal regarding the therapeutic options available in the future for critically ill patients with lower repiratory tract infections.

• There is an urgent need to implement strategies aimed at reducing the prevalence of multidrug-resistant Gram-negative pathogens causing lower respiratory tract infections.

Risk of Donor‐Derived Infections From Organ Donors Colonized or Infected With Multidrug‐Resistant Gram‐Negative Bacteria: A Systematic Review and Meta‐Analysis
Themistoklis Paraskevas, Christodoulos Chatzigrigoriadis, Ioannis D. Kostakis +8
Clinical transplantation1 Oct 2026Peer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
Distribution of gram-negative bacteria in lower respiratory tract infections and their susceptibility patterns to beta-lactam antibiotics during the COVID-19 pandemic
Conny Riana Tjampakasari, Reyhan Afif Sucahyo, Dimas Seto Prasetyo
Iranian Journal of Microbiology6 Nov 2026Peer-reviewedCC BY-NC 4.0Full textInfectious diseasePMC
Burden and risk factors of acquisition of multi-drug-resistant Gram-negative bacteria among intensive care patients at a tertiary care setting.
Majid M Alshamrani, Aiman El-Saed, Jaffar A Al-Tawfiq +6
Infection prevention in practice7 Aug 2026Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
Population Pharmacokinetics and Model-Informed Precision Dosing of Colistin Sulfate in Critically Ill Patients with Carbapenem-Resistant Gram-Negative Infections: A Prospective Pharmacokinetic-Pharmacodynamic Study.
Tianmin Huang, Lulu Niu, Luyao Qin +9
Drug design, development and therapy3 Nov 2026Peer-reviewedCC BY-NCFull textPharmacology & toxicologyEurope PMC
Early best available antibiotic therapy for multidrug-resistant gram-negative bloodstream infections: a target trial emulation
Luca Mezzadri, Wei Cong Tan, Xinxin Hao +102
eClinicalMedicine30 Oct 2026Peer-reviewedCC BY 4.0General medicineCrossref

Cite

BibTeX RIS

BibTeX

@article{golli2026burden,
  title = {{Burden of Resistant Gram Negative Bacteria in Lower Respiratory Tract Infections in ICU patients}},
  author = {A L Golli and M L Cara and F L Turcu and S G Popa},
  journal = {The European Journal of Public Health},
  year = {2026},
  month = oct,
  doi = {10.1093/eurpub/ckag169.1644},
  url = {https://doi.org/10.1093/eurpub/ckag169.1644},
  note = {CC BY-NC 4.0},
}

RIS

TY  - JOUR
TI  - Burden of Resistant Gram Negative Bacteria in Lower Respiratory Tract Infections in ICU patients
AU  - A L Golli
AU  - M L Cara
AU  - F L Turcu
AU  - S G Popa
PY  - 2026
DA  - 2026/10/01
JO  - The European Journal of Public Health
DO  - 10.1093/eurpub/ckag169.1644
UR  - https://doi.org/10.1093/eurpub/ckag169.1644
AB  - Background: Lower respiratory infections (LRTIs) represent the world’s deadliest infectious disease, responsible for approximately 2.5 million deaths worldwide. LRTIs are the most frequent infections among patients in the ICU (intensive care unit), often involving multidrug-resistant (MDR) pathogens.  Methods: We retrospectively analyzed 2582 clinical samples (479 sputum and 2103 endotracheal aspirates) from 2150 patients with LRTI admitted to the ICU of the Emergency Clinical County Hospital of Craiova, Romania, between 2022 and 2024.  Results: Gram-negative bacteria were responsible for 77.49% (3233) of the total of 4,172 bacterial isolates. The most frequently isolated pathogens were Klebsiella spp. (1168-36.13%), Acinetobacter spp. (935-28.92%), Pseudomonas spp. (414-12.81%), and Escherichia coli (332-10.27%). During the three-year period, the resistance rate of Acinetobacter spp. significantly increased for cefepime (from 74.09% to 94.25%, p < 0.001), imipenem (from 79.15% to 94.83%, p < 0.001), meropenem (from 88.63% to 94.95%, p < 0.05), piperacillin-tazobactam (from 86.67% to 94.39%, p = 0.001), and tigecycline (from 33.17% to 45.15%, p = 0.01). From 2022 to 2024, the resistance rate of Klebsiella spp. significantly increased for cefepime (from 47.70% to 55.71%, p < 0.05), imipenem (from 33.09% to 51.39%, p < 0.001), meropenem (from 33.09% to 52%, p < 0.001), ciprofloxacin (from 49.46% to 58.15%, p < 0.05), and levofloxacin (from 40% to 59.76%, p < 0.001). A significant decrease in resistance was found against tigecycline (from 34.91% to 13.88%, p < 0.001) and colistin (from 3.46% to 0.67%, p = 0.01). The rate of carbapenem-resistant Pseudomonas spp. strains significantly increased between 2022 and 2024 (from 41.72% to 56.93%, p = 0.01).  Conclusions: The data indicate an alarming increase in resistance to several first-line and last-resort antibiotics among Klebsiella spp. and Acinetobacter spp. strains, with progressive limitation of effective therapeutic options for ICU-LRTIs.  Key messages: • The emergence of resistant Gram-negative strains is an alarm signal regarding the therapeutic options available in the future for critically ill patients with lower repiratory tract infections.  • There is an urgent need to implement strategies aimed at reducing the prevalence of multidrug-resistant Gram-negative pathogens causing lower respiratory tract infections.
SN  - 1101-1262
SN  - 1464-360X
ER  -

Abstract

Related

Cite